首页/数据集/The combination of RMC4550 (SHP2 inhibitor) and LY3214996 (ERK inhibitor) effectively impairs tumor growth and induces tumor regression in multiplein vivo models of PDAC

The combination of RMC4550 (SHP2 inhibitor) and LY3214996 (ERK inhibitor) effectively impairs tumor growth and induces tumor regression in multiplein vivo models of PDAC

NIAID Data Ecosystem2026-03-14 收录

癌症药物组合治疗

SHP2/ERK抑制剂研究

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213706 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

应用场景：

创建时间：

2023-02-23

癌症药物组合治疗

PARP1抑制剂治疗

While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to

NIAID Data Ecosystem70

Combination of epigenetic, differentiation and DNA damaging agents induce tumor cell death and stem cell depletion in breast cancer. Homo sapiens

癌症药物组合治疗

基因表达调控

Gene expression profiles were performed on MDA-MB-231 TNBC cell line treated with entinostast, all-trans retinoic acid (ATRA), and doxorubicin as single, double, and triple combinations using Illumina

NIAID Data Ecosystem40

Potentiation of the Effect of Lonidamine by Quercetin in MCF-7 human breast cancer cells through downregulation of MMP-2/9 mRNA Expression

癌症药物组合治疗

RNA表达分析

Abstract Combination therapies are becoming increasingly important to develop an effective treatment in cancer. Lonidamine is frequently used in cancer treatment, but it’s often preferred to be used i

Figshare2020-03-01 更新30

Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines

癌症药物组合治疗

药物细胞毒性机制

Previously, Bithionol (BT) was shown to enhance the chemosensitivity of ovarian cancer cell lines to cisplatin treatment. In the present study, we focused on the anti-tumor potential of the BT-paclita

NIAID Data Ecosystem50

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations

PARP抑制剂耐药机制

癌症药物组合治疗

Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are requir

Figshare2016-10-13 更新30

The combination of RMC4550 (SHP2 inhibitor) and LY3214996 (ERK inhibitor) effectively impairs tumor growth and induces tumor regression in multiplein vivo models of PDAC

资源简介：

相关数据集